

Worried about Warfarin?

Here's some comforting news.



Iverson[™]
GENETIC DIAGNOSTICS, INC.

Warfarin worries? You're not alone.

If you're worried about the possible side effects of taking warfarin (brand name Coumadin®) for anticoagulation, you're not alone. Studies estimate that half the patients who could benefit from warfarin therapy are not receiving it.^{1,2} Part of the reason is fear of an unstable dosage—too little could result in a clot, and too much could cause excessive bleeding.

That uneasiness is understandable. We're all unique. And establishing a steady, tailor-made treatment for each individual is sometimes elusive. Patients often have to endure frequent lab visits, regular diet modifications and dosage fluctuation to reach a stable INR (International Normalized Ratio).

You're already anxious about your condition. You don't want to worry about your treatment, too.


If accurate warfarin dosing is a concern, ask your physician about genetic testing.

Peace of mind through genetic testing

By administering a painless genetic test, your doctor will discover if you have genetic variations known to inhibit warfarin's effectiveness. Acquiring this information is a huge step toward treatment that is safer, more effective and less costly in the long run.

Responses to warfarin treatment differ among patients. Factors such as age, weight and sex account for 10–20% of the differences. Genetic variations, however, account for up to 40%.³ So, by combining genetic testing with other considerations, your doctor can potentially address up to 60% of the factors that would cause you to respond negatively to warfarin. That means getting you on a safe and stable dose quicker. And that means peace of mind—something you can't express in percentages.

Ask your doctor about testing today. And start your warfarin treatment with assurance instead of anxiety.



FAQs

What do you mean by genetic variations?

There are two genes in the body (CYP2C9 and VKORC1) that, if sufficiently deviating from their normal structure, can cause inadequate response or increased risk of bleeding during warfarin treatment.

CYP2C9: sets the rate for accumulation and elimination of warfarin in the patient's body.

VKORC1: sets the effective concentration of warfarin in the individual patient, and is associated with specific warfarin maintenance dosing.

This test determines whether you have any variations in these genes that would cause problems with warfarin, and your doctor factors that information into your dosage.

Will my insurance cover it?

Medicare and insurance coverage decisions are made on a provider-by-provider basis. Your doctor will be able to help with insurance coverage information.

How is the test administered?

Our test is conducted on a sample taken with an oral swab, blood sample or saliva collection device.

Is genetic testing accepted by the medical community?

Yes. It is recommended by both the American Medical Association (AMA) and the U.S. Food and Drug Administration (FDA) prior to the start of warfarin therapy.⁴



References

1. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). *European Heart Journal* [Internet]. 2006 [cited 2008 Oct 24];27:1954-1964. Available from: <http://eurheartj.oxfordjournals.org/cgi/content/full/27/16/1954>
2. Mohr JP, M.D.; Thompson JLP, Ph.D.; Lazar RM, Ph.D.; Levin B, M.D.; Sacco RL, M.D.; Furie KL, M.D.; Kistler JP, M.D.; Albers GW, M.D.; Pettigrew LC, M.D.; Adams HP Jr., M.D., C.M., et al. A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke. *New England Journal of Medicine* [Internet]. 2001 [cited 2008 Oct 24];345(20):1444-1451. Available from: <http://content.nejm.org/cgi/content/full/345/20/1444>
3. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. *Blood Journal* [Internet]. 2005 [cited 2008 Oct 24];106:135-140. Available from: <http://bloodjournal.hematologylibrary.org/cgi/content/full/106/1/135>
4. FDA Approves Updated Warfarin (Coumadin) Prescribing Information [Internet]. U.S. Food and Drug Administration. 2007 [cited 2008 Oct 20]. Available from: <http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684>.



Iverson Genetic Diagnostics, Inc.
19805 North Creek Pkwy
Bothell, WA 98011

Telephone:
425.318.1332 direct
866.900.0903 toll free

Fax:
425.318.1795

Email:
info@iversongenetics.com

Website:
www.iversongenetics.com